These results show that CAPA is uniquely active against neuroblastoma cells and that specific CAPA analogues that are predicted to be more metabolically stable than CAPE can reproduce CAPA’s activity against neuroblastoma cells and CAPE’s activity against HeLa cells. Here, SMC2 is linked to neuroblastoma.